Gelonghui, April 26 | Luoxin Pharmaceutical (002793.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 689 million yuan, up 3.97% year on year; net profit attributable to shareholders of listed companies - 366.616 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 389.5599 million yuan; basic earnings per share - 0.03 yuan.
罗欣药业(002793.SZ)：一季度净亏损3666.16万元
Luoxin Pharmaceutical (002793.SZ): Net loss of 366.616 million yuan in the first quarter
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.